Please login to the form below

Not currently logged in
Email:
Password:

Pfizer scraps RA drug

Pfizer has decided to scrap development of TRU-015 for the treatment of rheumatoid arthritis

Pfizer has decided to scrap development of a drug for a very large market – rheumatoid arthritis (RA). Seattle-based Trubion Pharmaceuticals, which has a collaboration in RA with the company, said that Pfizer has terminated development of TRU-015, a protein therapeutic product.

The decision is based on a phase IIb study which did not meet its primary endpoint of a 20 per cent reduction on an American College of Rheumatology disease scoring index compared to placebo.

Trubion noted that Pfizer intends to continue development of another RA product that is part of the collaboration, SBI-087. That drug is currently in a phase II study.

15th June 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics